Market Update
Filed with ASX · · 3 pages · English
On 6ix: 6ix.com/news/market-update-66
Watch Mayne Pharma's latest callMayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call• Women’s Health: continued growth with demand for Total Prescriptions (TRx) showing continued volume growth through the first 5 months, up vs the prior corresponding period (pcp) o NEXTSTELLIS® +13.8%, BIJUVA® +30%, ANNOVERA® +15%, IMVEXXY® +5.8% • Dermatology: launch of TWYNEO® and EPSOLAY® improved gross margin (YTD in USD) to 64% from 52% vs pcp • International: accelerated growth of NEXTSTELL
Mayne Pharma Group Ltd. on 6ix
Earlier from Mayne Pharma
- Termination of Proposed Acquisition of Mayne Pharma
- Mayne Pharma terminates Scheme Implementation Deed
- MYX receives purported termination notice from Cosette
- Mayne Pharma issues notice of intention to terminate the SID
- Update on FIRB condition and scheme
Later from Mayne Pharma
- 2025 AGM presentation and business update
- MYX to claim against Cosette, Avista & Mr David Burgstahler
- Mayne Pharma Management Changes
- Half Yearly Report and Accounts
- 2026 Half Year Media Release
Follow Mayne Pharma into a list and get an email when it puts out news.
Follow Mayne Pharma